Designing nanoformulation for the nose‐to‐brain delivery in Parkinson's disease: Advancements and barrier

2021 ◽  
Author(s):  
Pallavi Kiran ◽  
Sujit Kumar Debnath ◽  
Suditi Neekhra ◽  
Vaishali Pawar ◽  
Amreen Khan ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Brain Delivery

GOCOVRI® (amantadine) extended-release capsules in Parkinson's disease

2021 ◽  
Author(s):  
Thomas Müller
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Extended Release ◽  
Motor Behavior ◽  
Brain Delivery ◽  
Antiviral Compound ◽  
Once Daily ◽  
Beneficial Effects ◽  
Central Monoamine ◽  
Preventive Effects

Amantadine is an old, antiviral compound, which moderately improves motor behavior in Parkinson's disease. Its current resurgence results from an innovative, delayed uptake and extended release amantadine hydrochloride capsule, given at bedtime once daily. It is the only approved compound for reduction of involuntary movements, so called dyskinesia, in fluctuating orally levodopa treated patients. It additionally ameliorates ‘off’-intervals characterized by impaired motor behavior. These beneficial effects result from higher and more continuous brain delivery of amantadine. Future clinical research is warranted on preventive effects of this amantadine capsule combined with enzyme blockers of central monoamine oxidase B and peripheral catechol-O-methyltransferase on motor complications in orally levodopa treated patients, as all these pharmacological principles support the concept of continuous dopamine substitution.

scholarly journals Effective GDNF brain delivery using microspheres—A promising strategy for Parkinson's disease

2009 ◽  
Vol 135 (2) ◽  
pp. 119-126 ◽  
Author(s):  
E. Garbayo ◽  
C.N. Montero-Menei ◽  
E. Ansorena ◽  
J.L. Lanciego ◽  
M.S. Aymerich ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Brain Delivery ◽  
Promising Strategy

Nanoparticles Mediating the Sustained Puerarin Release Facilitate Improved Brain Delivery to Treat Parkinson’s Disease

2019 ◽  
Vol 11 (48) ◽  
pp. 45276-45289 ◽  
Author(s):  
Tongkai Chen ◽  
Wei Liu ◽  
Sha Xiong ◽  
Dongli Li ◽  
Shuhuan Fang ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Brain Delivery

Lactoferrin conjugated PEG-PLGA nanoparticles for brain delivery: Preparation, characterization and efficacy in Parkinson's disease

2011 ◽  
Vol 415 (1-2) ◽  
pp. 273-283 ◽  
Author(s):  
Kaili Hu ◽  
Yanbin Shi ◽  
Wenming Jiang ◽  
Jiaying Han ◽  
Shixian Huang ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Plga Nanoparticles ◽  
Brain Delivery

Nose to brain delivery of rotigotine loaded chitosan nanoparticles in human SH-SY5Y neuroblastoma cells and animal model of Parkinson's disease

2020 ◽  
Vol 579 ◽  
pp. 119148 ◽  
Author(s):  
Subrat K. Bhattamisra ◽  
Angeline Tzeyung Shak ◽  
Lim Wen Xi ◽  
Nurul Hasyanazifa Safian ◽  
Hira Choudhury ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Animal Model ◽  
Chitosan Nanoparticles ◽  
Neuroblastoma Cells ◽  
Brain Delivery

scholarly journals Nose ‐To ‐Brain Delivery of Mitochondria for Treatment of Parkinson’s Disease Model Rats With 6-Hydroxydopamine

2020 ◽  
Author(s):  
Jui-Chih Chang ◽  
Yi-Chun Chao ◽  
Huei-Shin Chang ◽  
Yu-Ling Wu ◽  
Hui-Ju Chang ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Olfactory Bulb ◽  
Disease Model ◽  
Organelle Transport ◽  
Brain Delivery ◽  
Ipsilateral Side ◽  
6 Hydroxydopamine ◽  
Locomotor Behaviors ◽  
Migratory Stream

Abstract BackgroundFeasibility of mitochondrial organelle transport via the olfactory bulb route for Parkinson's disease (PD) therapy was evaluated in the unilateral 6-OHDA-lesioned rats due to the distinct difference based on payload properties. MethodsAn intranasal infusion with 200 μg of allogeneic mitochondria conjugated with Pep-1 (P-Mito) or not (Mito) was executed once a week at the ipsilateral side of lesioned brain for three months of treatments.Results A significant improvement of rotational and locomotor behaviors in PD rats was found in both mitochondria-treating groups in contrast to Sham group or Pep-1 group. There was more than 60% recovery survival of dopaminergic (DA) neurons in substantia nigra (SN) and striatum (ST) of lesioned sides compared to the intact sides in groups of Mito and P-Mito. Treatment effect in P-Mito group was higher in the P-Mito group than Mito group but not significant. The mechanism was associated with the restoration of mitochondrial function and attenuation of oxidative damage in lesioned SN. Notably, Pep-1 modification suppressed the plasma level of inflammatory cytokines induced by infused mitochondria. The 5-bromo-2-deoxyuridine-labelled tracks showed the mitochondrial penetrating into doublecortin-positive neurons of rostral migratory stream (RMS) along with the accessory olfactory bulb in ipsilateral side of lesion and it was expressed in striatal DA neurons, but not in SN, of two cerebral hemispheres via commissural fibers. Conclusion This study showed a promising approach of nose-to-brain delivery for mitochondrial transplantation by confirming the mitochondrial internalization via RMS neurons migration in olfactory bulb for therapeutic action of PD in rats.

Sign in / Sign up

Export Citation Format

Share Document